No Carolina / NY / Florida
Ph: 561.316.3330

No Carolina | NY | Florida

BioZone Scientific Technology Independently Confirmed to Be Effective Against SARS-CoV-2, the Virus That Causes COVID-19

Editor: What To Know

  • These accredited test results are the latest in a long line of groundbreaking and independently verified test programs that have been undertaken by BioZone Scientific, including research on the effectiveness of our technology against viruses by the French Centre for National Virology Research and papers published in the Journal of Clinical Virology.
  • A leading manufacturer in HVAC UV light solutions for the disinfection of air and surfaces, BioZone ​Scientific technology has been used by thousands of people around the world for safe disinfection of homes, restrooms, transport, and businesses.
  • The testing was conducted by BioZone Scientific Technology Laboratories, an ISO/IEC 17025 certified Florida, USA-based lab which is also accredited by the US Centers for Disease Control, US Environmental Protection Agency, US Department of Agriculture, and Florida Department of Health.

December 10, 2020

BioZone Scientific Technology residential, commercial, and healthcare products were independently tested for effectiveness against SARS-CoV-2 by a third-party lab.

In the test report titled, “SARS-CoV-2 Surrogate Inactivation by Ultraviolet Disinfection System from BioZone Scientific,” the systems repeatedly delivered greater than 5-log inactivation (>99.999%) of the SARS-CoV-2 virus in less than one second of exposure to BioZone Scientific ultraviolet disinfection systems.

The testing was conducted by BioZone Scientific Technology Laboratories, an ISO/IEC 17025 certified Florida, USA-based lab which is also accredited by the US Centers for Disease Control, US Environmental Protection Agency, US Department of Agriculture, and Florida Department of Health. The test was designed to model exposure time comparative to inactivating the SARS-CoV-2 virus in the moving airstream within HVAC systems.

A leading manufacturer in HVAC UV light solutions for the disinfection of air and surfaces, BioZone ​Scientific technology has been used by thousands of people around the world for safe disinfection of homes, restrooms, transport, and businesses.

This study joins others, including those published in the Journal of Clinical Virology, that demonstrate that BioZone ​Scientific’s advanced ultraviolet disinfection systems are effective at inactivating viruses and other infectious diseases.

Paul Morris, BioZone ​Scientific’s Senior Vice President for Global Business Development, stated, “This is more welcome evidence that BioZone ​Scientific’s long experience of delivering innovative and effective Biological Defense systems for our clients is based on several critical philosophies – innovation, responsiveness to our clients’ needs, and sound, certified, scientific data. These accredited test results are the latest in a long line of groundbreaking and independently verified test programs that have been undertaken by BioZone Scientific, including research on the effectiveness of our technology against viruses by the French Centre for National Virology Research and papers published in the Journal of Clinical Virology.

This long term and consistent approach gives BioZone ​Scientific’s partners the confidence that they are working with technology that is always ahead of the field in terms of reliability, quality, and effectiveness. We believe this approach is at the center of our success, and the success of our clients.”

Ari Ahola, CEO of BioZone Scientific, stated, “These third-party test results show that BioZone Scientific systems are essential in delivering virus-free environments and are critical components of return to work protocols. In less than a second, BioZone solutions are capable of disinfection rates almost below the levels of detection. We’re immensely proud of these findings, which are well in line with other scientific tests of BioZone ​Scientific technologies. Our mission is to limit the spread of COVID-19 and help people to return to work safely.”

BioZone Scientific Technology is the leader in ultraviolet disinfection systems and has been at the forefront of UV technology for decades. It has a proven track record of innovation in disinfection technologies, which are designed, manufactured, and installed in line with the highest safety standards.

Visit BioZone ​Scientific Technology COVID-19 validation testing.

Other Biotechnology News

Hyundai Bioscience Announces Clinical Development Plan for Niclosamide-based Metabolic Anticancer Drug Targeting P53 Mutation Cancer

Sang-ki Oh, CEO of Hyundai Bioscience, stated, "Niclosamide-based metabolic anticancer drug candidate will be the first P53-targeting anticancer treatment that selectively kills p53 mutated cancer cells," and added, "Through our subsidiary ADM Korea, we plan to conduct clinical trials targeting cancer patients with intractable cancer caused by p53 mutations, which will be the first step of clinical development on niclosamide-based anticancer agent pipeline."

Preci and Biopredic International Partner for Higher Performance of Suspended Pooled Hepatocytes with Extended Longevity and Large-scale Availability

Under a license agreement, Biopredic will leverage Preci’s expertise and production capacity in sourcing primary hepatocytes, and combine with its own IP and know-how in cell pooling. The partnership will provide DMPK researchers access to large batches of high-performing suspended pooled hepatocytes with extended longevity from multiple donors.

The Future of Biotechnology: Insights Into Cutting-Edge Developments

The future of biotechnology holds immense promise, with continued advancements driving innovation and progress across various sectors. From gene editing and synthetic biology to biopharmaceuticals and beyond, the possibilities are endless. By staying informed, collaborating with industry leaders, and leveraging cutting-edge technologies, we can harness the power of biotechnology to address some of the most pressing challenges facing humanity.

Advancing Patient Care: LyGenesis Doses First Patient in Phase 2a Trial

"In a medical first, we have now dosed our first patient in a clinical trial using their own lymph nodes as living bioreactors to regenerate an ectopic organ," said Dr. Michael Hufford, Co-Founder and CEO of LyGenesis. "This therapy will potentially be a remarkable regenerative medicine milestone by helping patients with ESLD grow new functional ectopic livers in their own body. If our study is successful and we obtain FDA approval, our allogenic cell therapy could enable one donated liver to treat many dozens of ESLD patients, which could help to tilt the current organ supply-demand imbalance in favor of patients."

spot_img

By using this website you agree to accept Medical Device News Magazine Privacy Policy